PharmaVentures Acts as Advisor and Broker to Dr Reddy's to Identify and Secure Product Marketing Opportunities for the Russian/CIS Market

OXFORD, England, October 26, 2010 - PharmaVentures Ltd announced today that it had acted as the advisor and
broker to the Indian pharmaceutical company Dr Reddy's Laboratories in its
successful marketing and distribution agreement with the UK healthcare
company Vitabiotics Ltd for a range of nutraceutical products. The agreement
provides Dr Reddy's exclusive marketing rights in the Russian/CIS markets for
two of Vitabiotics' leading products - Jointace and Dietrim. Vitabiotics will
supply these products on a long-term basis from its facilities in Europe.

The engagement with Dr Reddy's utilised PharmaVentures' significant and
established pharmaceutical transactions experience in the healthcare
transactions sector. Dr Fintan Walton, Chief Executive, PharmaVentures said,
"We are delighted to bring another successful outcome to one of our important
international clients, Dr Reddy's. We are proud to have acted as advisor and
broker to one of India's premier pharmaceutical companies, particularly in
assisting them to achieve their business goals in the increasingly expanding
Russian/CIS market."

PharmaVentures acted as advisor and broker to the Dow Chemical
Corporation in the sale of its small molecule pharmaceutical manufacturing
business to Dr Reddy's, under a separate agreement in 2008.

Over the past 18 years, PharmaVentures has acted as advisors to numerous
pharmaceutical and biopharmaceutical clients in transactions covering the
licensing, merger, acquisition, divestment and joint venture activities for
companies located worldwide.

Notes to Editors:

PharmaVentures(R) (www.pharmaventures.com) is a leading
international corporate advisory firm supporting its clients' growth
ambitions in the health care industry. It has considerable experience and
expertise in the field of tangible and intangible transactions, providing
advice at both a strategic level, as well as acting as advisor and broker at
an implementation level. Its transactional experience includes licensing,
joint ventures, mergers, acquisitions and divestments. Its clients are
worldwide, including Europe, the USA and AsiaPacific. Clients range from
start-ups to global pharmaceutical corporations, diversified industrial
corporations, investment houses and government bodies. Its subsidiary
PharmaTelevision produces the highly popular PharmaDeals(R) range of
intelligence products including analysis tools and reports as well as the
world's first dedicated online pharmaceutical television channel
PharmaTelevision(R) (www.pharmatelevision.com).

Now in its 18th year, PharmaVentures is based in Oxford, UK, and employs
over 30 people.

    For press enquiries, please contact:

    Dr Fintan Walton, CEO
    PharmaVentures
    fintan.walton@pharmaventures.com
    +44(0)1865-332700

For press enquiries, please contact: Dr Fintan Walton, CEO, PharmaVentures, fintan.walton at pharmaventures.com, +44(0)1865-332700